Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
Illumina reported Q3 FY26 revenue of $1.13 billion, up 4.2% year-over-year (7.6% growth excluding tariff refunds), with results above guidance driven by healthy clinical demand and robust NovaSeq X placements. GAAP diluted EPS was $1.43 versus $0.98 a year earlier; non-GAAP diluted EPS excluding tariff refunds was $1.44. Free cash flow rose to $378 million from $253 million. Management raised FY26 guidance: revenue to $4.64-$4.66 billion (from $4.60-$4.64 billion) and non-GAAP diluted EPS to $5.40-$5.45 (from $5.30-$5.40).
Key figures
- Eps
- 1.43
- Revenue
- 1129000000
- Guidance
- FY26 revenue $4.64-$4.66B (raised from $4.60-$4.64B); non-GAAP operating margin 23.6%; non-GAAP diluted EPS $5.40-$5.45 (raised from $5.30-$5.40)
- Revenue Yoy
- 4.2%
- Fcf
- 378000000
- Capex
- 41000000
- Net income
- 220000000
- Non gaap eps
- 1.62
- Gross margin gaap
- 73.5%
- Operating cash flow
- 419000000
- Gaap operating margin
- 27.0%
- Organic revenue growth
- 4.8%
- Row organic revenue growth
- 4.7%
- Non gaap eps ex tariff refunds
- 1.44
- Cash and short term investments
- 1340000000
- Tariff refund revenue reduction
- 37000000
- Tariff refund cost of revenue benefit
- 79000000
- Non gaap operating margin ex tariff refunds
- 25.0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.